Prognosis
U.S. Seeks ‘Urgent’ Data on Covid Relapses After Using Pfizer’s Drug
- Columbia researcher says symptoms returned days after Paxlovid
- How common viral rebound is after Paxlovid remains unclear
This article is for subscribers only.
U.S. government researchers are planning studies of how often and why coronavirus levels rebound in some Covid patients who have completed a five-day course of treatment with Pfizer Inc.’s Paxlovid.
“It is a priority,” said Clifford Lane, deputy director for clinical research at the National Institute of Allergy and Infectious Diseases, calling the issue “a pretty urgent thing for us to get a handle on.” The agency is discussing a variety of possible epidemiological and clinical studies to examine post-Paxlovid rebound with scientists at the Centers for Disease Control and Prevention, he said.